The effect of Virtual Reality on pulmonary recovery and mobility in patients with blunt chest trauma.

The effect of Virtual Reality on pulmonary recovery and mobility in patients with blunt chest trauma. - VR Trauma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON50573

Enrollment

126

Registered

2022-02-02

Start date

2022-03-28

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blunt chest injury Blunt chest trauma

Interventions

All patients from both groups will receive care according to existing guidelines (Guideline: *thoraxwandletsels*). Similarly, pain management will be according to the standardized Radboudumc guideli

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Admitted to the trauma ward with sustained blunt chest trauma - Age>=16 - Patient is willing and able to comply with the study protocol

Exclusion criteria

Exclusion criteria: - Neurotrauma with GCS

Design outcomes

Primary

Measure	Time frame
mean daily inspiration volume in mL, measured with an incentive spirometer (Voldyne).	—

Secondary

Measure	Time frame
Patient mobility:Time spent lying, sitting and moving measured with a wearable activity monitor (ActivPal/Activ8). Clinical outcomes: Length of hospital stay in days, pulmonary complications during admission, transfer to ICU, readmission within 30 days Pain: VAS score during breathing exercise, analgesic use (paracetamol, NSAIDs, opioids), use of add-on/escape medication Activities of daily livin: Powerlessness in Daily Living questionnaire (PDL) Patient reported outcomes: Quality of Recovery-15 questionnaire, treatment satisfaction questionnaire Safety outcomes: Reasons for withdrawal, adverse events during VR therapy incl. virtual reality sickness questionnaire (VRSQ) Barriers to implementation: Treatment adherence, measured by the number of times pulmonary and physical exercise are performed, technical problems, feedback on apps.	—

Measure

Time frame

Patient mobility:Time spent lying, sitting and moving measured with a wearable activity monitor (ActivPal/Activ8). Clinical outcomes: Length of hospital stay in days, pulmonary complications during admission, transfer to ICU, readmission within 30 days Pain: VAS score during breathing exercise, analgesic use (paracetamol, NSAIDs, opioids), use of add-on/escape medication Activities of daily livin: Powerlessness in Daily Living questionnaire (PDL) Patient reported outcomes: Quality of Recovery-15 questionnaire, treatment satisfaction questionnaire Safety outcomes: Reasons for withdrawal, adverse events during VR therapy incl. virtual reality sickness questionnaire (VRSQ) Barriers to implementation: Treatment adherence, measured by the number of times pulmonary and physical exercise are performed, technical problems, feedback on apps.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)